What up Bros Nation! How is it going?! I don’t know about you but this past week has felt kind of long with no midweek Money Talkz check in. How has the market been treating you? In my case I had my shares of ups and downs but for the week I’m up several hundred dollars across various investments. On the crypto side of things I’d say about the same. I’m up over seven hundred dollars through various crypto investments. Slow and steady progress while waiting for that one breakout. Anyway, welcome to another episode of Money Talk Sundayz. It’s your big bro Stevie Bee. Hit that like share and subscribe button on your way in the door. Let’s get to the news.

Call it the stock market’s version of the “sequel effect.” January’s meme stock runup was so enjoyable that investors can’t help but try short squeezes again. This week, the 15 most shorted stocks have risen 31%, wildly outperforming the S&P 500’s 0.76% gain over the same time. SPACs are just collateral damage of attention-deficit investors.

Vaxart, vaxart, vaxart. While doing my review of Vaxart for today’s episode I came across another biotech stock that’s competing with VXRT. That company is Oramed Pharmaceuticals. Oramed is a pharmaceutical company. It is engaged in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. Its pipeline products are ORMD-0801 Type 1, ORM-0801 Type 2 and ORMD-0901. Its flagship product, ORMD-0801, is an orally ingestible insulin capsule. It is anticipated for use as a complementary agent to insulin injections in the treatment of Type I diabetes Mellitus (T1DM) and T2Dm disease. This treatment regimen should allow for fewer daily injections and a lower frequency of blood glucose fluctuations in cases of unstable and brittle T1DM.

Knowing there is another company working on a Covid pill how do they compare? Let’s start with the house favorite, VXRT.

Off rip, Vaxart has already obtained the FDA approval to begin phase 2 clinical trials with its tablet vaccine candidate. That trial will be commencing shortly. As of this recording VXRT is trading at 8.71. It closed Friday September 3rd 11 cents below it’s 20 day moving average with a trading volume of 2.89 million. The firm has a fifty day simple moving average of $8.17 and a 200-day simple moving average of $7.30. The company has a market capitalization of $1.10 billion.

Notably, Julie M. Cherrington joined VXRT Board of Directors. When Julie joined the board of Rakovina Therapeutics this is what they had to say about her.

"Julie M. Cherrington is an accomplished life science executive with a record of demonstrated success bringing drug candidates into human clinical trials and through to commercialization. She has been a key contributor to the successful development of multiple FDA-approved products…”

She is a driving force for multiple products getting FDA approved and moved to market. She’s also served on the board of Arch Oncology, Revitope Oncology, Zenith Epigenetics, and Pathway Therapeutics to name a few.

Dr. Cherrington holds a B.S. in biology and an M.S. in microbiology from the University of California, Davis. She earned a Ph.D. in microbiology and immunology from the University of Minnesota and Stanford University. She completed a postdoctoral fellowship at the University of California, San Francisco.

Her credentials are not to be effed with at all. With that being said, Vaxart is in a good place to make some real game changing moves.

Oramed on the other hand has a few factors tipping the scale in their favor. Oramed (ORMP) has outperformed even Moderna (NASDAQ:MRNA) and BioNTech (NASDAQ:BNTX), the established vaccine makers that have already received FDA authorization for their messenger-RNA-based shots.